Revelation Biosciences Net Income
| REVB Stock | USD 1.41 0.06 4.44% |
As of the 26th of February, Revelation Biosciences holds the Variance of 33.16, risk adjusted performance of (0.15), and Coefficient Of Variation of (496.28). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Revelation Biosciences, as well as the relationship between them.
Revelation Biosciences Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -13.5 M | -12.9 M | |
| Net Loss | -1.9 M | -1.8 M | |
| Net Loss | -13.5 M | -12.9 M | |
| Net Loss | (78.91) | (82.86) | |
| Net Income Per E B T | 0.39 | 0.34 |
Revelation | Net Income | Build AI portfolio with Revelation Stock |
Analyzing Revelation Biosciences's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Revelation Biosciences's current valuation and future prospects.
Latest Revelation Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Revelation Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Revelation Biosciences financial statement analysis. It represents the amount of money remaining after all of Revelation Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Revelation Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Revelation Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (15.04 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Revelation Net Income Regression Statistics
| Arithmetic Mean | 993,773 | |
| Geometric Mean | 3,367,415 | |
| Coefficient Of Variation | 1,143 | |
| Mean Deviation | 8,524,475 | |
| Median | 4,505,000 | |
| Standard Deviation | 11,357,409 | |
| Sample Variance | 129T | |
| Range | 42.7M | |
| R-Value | (0.61) | |
| Mean Square Error | 87.2T | |
| R-Squared | 0.37 | |
| Significance | 0.01 | |
| Slope | (1,361,703) | |
| Total Sum of Squares | 2063.9T |
Revelation Net Income History
Other Fundumenentals of Revelation Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Revelation Biosciences Net Income component correlations
Revelation Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Revelation Biosciences is extremely important. It helps to project a fair market value of Revelation Stock properly, considering its historical fundamentals such as Net Income. Since Revelation Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Revelation Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Revelation Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. Anticipated expansion of Revelation directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Revelation Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Revelation Biosciences requires distinguishing between market price and book value, where the latter reflects Revelation's accounting equity. The concept of intrinsic value - what Revelation Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Revelation Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Revelation Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Revelation Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Revelation Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Revelation Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Revelation Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Revelation Biosciences.
| 11/28/2025 |
| 02/26/2026 |
If you would invest 0.00 in Revelation Biosciences on November 28, 2025 and sell it all today you would earn a total of 0.00 from holding Revelation Biosciences or generate 0.0% return on investment in Revelation Biosciences over 90 days. Revelation Biosciences is related to or competes with Scisparc, Onconetix, Indaptus Therapeutics, GT Biopharma, Avenue Therapeutics, Psyence Biomedical, and Azitra. Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercializati... More
Revelation Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Revelation Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Revelation Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.22) | |||
| Maximum Drawdown | 35.57 | |||
| Value At Risk | (10.16) | |||
| Potential Upside | 6.84 |
Revelation Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Revelation Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Revelation Biosciences' standard deviation. In reality, there are many statistical measures that can use Revelation Biosciences historical prices to predict the future Revelation Biosciences' volatility.| Risk Adjusted Performance | (0.15) | |||
| Jensen Alpha | (1.39) | |||
| Total Risk Alpha | (1.91) | |||
| Treynor Ratio | (0.53) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Revelation Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Revelation Biosciences February 26, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | (0.52) | |||
| Mean Deviation | 3.99 | |||
| Coefficient Of Variation | (496.28) | |||
| Standard Deviation | 5.76 | |||
| Variance | 33.16 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (1.39) | |||
| Total Risk Alpha | (1.91) | |||
| Treynor Ratio | (0.53) | |||
| Maximum Drawdown | 35.57 | |||
| Value At Risk | (10.16) | |||
| Potential Upside | 6.84 | |||
| Skewness | (1.00) | |||
| Kurtosis | 3.72 |
Revelation Biosciences Backtested Returns
Revelation Biosciences maintains Sharpe Ratio (i.e., Efficiency) of -0.25, which implies the firm had a -0.25 % return per unit of risk over the last 3 months. Revelation Biosciences exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Revelation Biosciences' Risk Adjusted Performance of (0.15), coefficient of variation of (496.28), and Variance of 33.16 to confirm the risk estimate we provide. The company holds a Beta of 2.2, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Revelation Biosciences will likely underperform. At this point, Revelation Biosciences has a negative expected return of -1.47%. Please make sure to check Revelation Biosciences' potential upside, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Revelation Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.61 |
Good predictability
Revelation Biosciences has good predictability. Overlapping area represents the amount of predictability between Revelation Biosciences time series from 28th of November 2025 to 12th of January 2026 and 12th of January 2026 to 26th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Revelation Biosciences price movement. The serial correlation of 0.61 indicates that roughly 61.0% of current Revelation Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.61 | |
| Spearman Rank Test | 0.67 | |
| Residual Average | 0.0 | |
| Price Variance | 0.8 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Revelation Biosciences reported net income of (15.04 Million). This is 104.41% lower than that of the Biotechnology sector and 121.47% lower than that of the Health Care industry. The net income for all United States stocks is 102.63% higher than that of the company.
Revelation Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Revelation Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Revelation Biosciences could also be used in its relative valuation, which is a method of valuing Revelation Biosciences by comparing valuation metrics of similar companies.Revelation Biosciences is currently under evaluation in net income category among its peers.
Revelation Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Revelation Biosciences from analyzing Revelation Biosciences' financial statements. These drivers represent accounts that assess Revelation Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Revelation Biosciences' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 402.8M | 43.0M | 41.2M | 15.2M | 17.5M | 16.6M | |
| Enterprise Value | 401.5M | 37.8M | 29.2M | 8.7M | 10.0M | 9.5M |
Revelation Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Revelation Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Revelation Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Revelation Biosciences' value.| Shares | Tower Research Capital Llc | 2025-03-31 | 2 K | Sbi Securities Co Ltd | 2025-06-30 | 1.4 K | Royal Bank Of Canada | 2025-03-31 | 1.4 K | Ubs Group Ag | 2025-03-31 | 349 | Bank Of America Corp | 2025-03-31 | 18.0 | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 0.0 | Ifp Advisors, Llc | 2025-06-30 | 0.0 | Xtx Topco Ltd | 2025-03-31 | 0.0 | Two Sigma Securities, Llc | 2025-03-31 | 0.0 |
Revelation Fundamentals
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | (1.59 M) | ||||
| Shares Outstanding | 2.62 M | ||||
| Shares Owned By Insiders | 1.69 % | ||||
| Shares Owned By Institutions | 11.73 % | ||||
| Number Of Shares Shorted | 258.21 K | ||||
| Price To Earning | 8.69 X | ||||
| Price To Book | 0.94 X | ||||
| Price To Sales | 2.88 X | ||||
| Gross Profit | 90.91 M | ||||
| EBITDA | (7.95 M) | ||||
| Net Income | (15.04 M) | ||||
| Cash And Equivalents | 3.48 M | ||||
| Cash Per Share | 0.15 X | ||||
| Total Debt | 1.91 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 0.68 X | ||||
| Book Value Per Share | 12.27 X | ||||
| Cash Flow From Operations | (18.32 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | 325.00 X | ||||
| Target Price | 85.0 | ||||
| Beta | -0.13 | ||||
| Market Capitalization | 3.54 M | ||||
| Total Asset | 6.62 M | ||||
| Retained Earnings | (40.51 M) | ||||
| Working Capital | 4.65 M | ||||
| Net Asset | 6.62 M |
About Revelation Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Revelation Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revelation Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revelation Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:Check out For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. Anticipated expansion of Revelation directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Revelation Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Revelation Biosciences requires distinguishing between market price and book value, where the latter reflects Revelation's accounting equity. The concept of intrinsic value - what Revelation Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Revelation Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Revelation Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Revelation Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Revelation Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.